Form 4: Replimune Director Christy Oliger Granted 44,500 Options

Replimune Group director Christy J. Oliger received a grant of 44,500 stock options with a ten-year term and a one-year vesting cliff.

Summary

• Director Christy J. Oliger was granted 44,500 stock options on April 1, 2026.
• The options carry an exercise price of $7.61 per share.
• The entire grant is scheduled to vest on April 1, 2027.
• The options have an expiration date of April 1, 2036.
• The disclosure was submitted to the SEC on April 7, 2026, following an administrative delay.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while the grant is a standard incentive, the late filing is a minor administrative oversight that does not impact fundamental value.

Positives

• Aligns director compensation with long-term shareholder interests through a 10-year option duration.
• The exercise price of $7.61 establishes a clear performance baseline for the director's equity incentive.

Negatives

• The filing was submitted late, representing a minor failure in meeting the standard two-business-day SEC reporting deadline.

Risks

• The options will only have value if the company's share price exceeds $7.61 after the vesting date in 2027.
• Potential for future share dilution of 44,500 shares upon the exercise of these options.

Future Outlook

The director's equity is tied to a one-year vesting cliff, indicating a focus on corporate performance through at least April 2027.

Management Comments

• This Form 4 is being filed late due to inadvertent administrative error.

Industry Context

StockSavvy.ai notes that equity-based compensation is a standard mechanism in the biotech industry to conserve cash while incentivizing board members to achieve clinical and regulatory milestones.

Comparison to Industry Standards

• The grant of 44,500 options is within the typical range for non-employee directors at mid-cap biotechnology firms.
• A one-year cliff vesting schedule is a common standard for annual director equity awards among NASDAQ-listed life sciences companies.

Corporate Governance

Related Party Transactions

• Grant of 44,500 stock options to Director Christy J. Oliger as part of standard compensation.

Stakeholder Impact

• Shareholders face minor potential dilution upon option exercise.
• Board alignment with long-term stock performance is reinforced.

Next Steps

• Full vesting of the options on April 1, 2027.

Key Dates

Keywords

Replimune Group, REPL, Stock Options, Director Compensation, SEC Form 4, Insider Trading, Biotechnology